# Skinvisible, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Skinvisible, Inc.). ## Overview Skinvisible, Inc. is a U.S.-based pharmaceutical research and development company focused on its patented Invisicare® polymer delivery system and a portfolio of topical skin products. Through its wholly owned subsidiary, Skinvisible Pharmaceuticals Inc., it develops and out-licenses prescription, over-the-counter, and other topical or transdermal formulations to third-party manufacturers and marketers worldwide. ## Products & services • Invisicare® polymer delivery technology • Topical prescription product formulations • Over-the-counter skin care formulations • Product out-licensing and royalty agreements • Co-development of topical drug formulations • Life-cycle management reformulations - **Invisicare® delivery platform** (0%) — Patented polymer-based skin delivery system used to formulate topical and transdermal products. - **Licensed topical formulations** (55%) — Prescription and OTC products developed with Invisicare and licensed to third parties. - **Royalty income** (25%) — Ongoing royalties from commercialized licensed products and sublicensing arrangements. - **Co-development services** (10%) — Early-stage formulation support for pharmaceutical clients before clinical development. - **Life-cycle management solutions** (10%) — Reformulation work for products coming off patent to extend product value. - Invisicare® polymer delivery technology - Topical prescription product formulations - Over-the-counter skin care formulations - Product out-licensing and royalty agreements - Co-development of topical drug formulations - Life-cycle management reformulations ## Customers Skinvisible sells primarily to pharmaceutical companies, consumer health companies, and other brand owners that need topical formulations or a delivery platform they can commercialize under their own brands. Its customers typically buy for access to patented formulation science, faster product development, and a way to extend or differentiate existing products. - **Pharmaceutical licensees** (primary) — Buy patented topical or transdermal formulations for development and commercialization. - **Consumer health and OTC brands** (primary) — License skin-care and over-the-counter formulations for branded consumer products. - **Development partners** (secondary) — Use co-development support to optimize formulations before clinical testing. - **Life-cycle management clients** (secondary) — Seek reformulations and line extensions for products facing patent expiry. - Pharmaceutical companies licensing topical drug formulations - Consumer goods and OTC brands seeking skin-care products - Companies needing reformulations for products coming off patent - Partners that want early-stage formulation support - Licensees that commercialize products and pay upfront fees/royalties ## Geography Skinvisible is headquartered in the United States, but its licensing model is global and its products are out-licensed to manufacturers and marketers internationally. The company’s commercial exposure is therefore tied to where licensees develop, approve, and sell Invisicare-based products, including the United States and Europe. - Headquartered in the United States - Licensing and royalty model is global in scope - Commercial partners operate across multiple international markets - Regulatory approvals in the U.S. and Europe can trigger milestones - Geographic exposure depends on licensee commercialization success ## Strategy Skinvisible’s strategy is to monetize its patented Invisicare platform through out-licensing, royalties, and co-development rather than building a large internal manufacturing footprint. It also seeks to extend the platform into adjacent medical markets where a topical or transdermal delivery approach can replace more invasive alternatives. - **Commercialize existing Invisicare licenses** (short-term) — Upfront fees and royalties are the core monetization path for the platform. - **Expand partner pipeline** (medium-term) — More licensees increase the number of products that can reach market without heavy internal capex. - **Broaden addressable markets** (long-term) — Applying Invisicare outside dermatology can enlarge the commercial opportunity set. - Out-license patented formulations to established manufacturers - Collect upfront fees, milestones, and ongoing royalties - Support co-development to improve partner formulations - Use life-cycle management to address patent-expiry opportunities - Expand Invisicare into adjacent medical markets beyond dermatology ## Risks Skinvisible depends on third parties to advance, approve, and commercialize licensed products, so revenue timing and scale are tied to partner execution and regulatory outcomes. As a development-stage licensing company, it also faces financing risk, intellectual property risk, and the possibility that its platform does not gain broad commercial adoption. - **Partner execution risk** [high] — Royalties and milestones depend on licensees advancing products through development and approval. - **Financing risk** [critical] — The company may need external capital to fund operations before licensing cash flows scale. - **Intellectual property risk** [high] — The business model relies on patents protecting Invisicare and related formulations. - **Regulatory approval risk** [high] — Milestones and commercialization can be delayed or blocked by FDA/EU review outcomes. - Revenue depends on partner commercialization and regulatory approvals - Limited cash resources create financing and going-concern pressure - Patent protection is central to the licensing model - Licensees may delay, discontinue, or underperform on product launches - Early-stage biotech/pharma demand can be volatile and uncertain ## Accounting Skinvisible recognizes product sales when title transfers and royalty revenue when earned, so reported revenue depends on contract terms and the timing of partner commercialization. Investors should also watch estimates around intangible assets, debt and payables, and any impairment or collectability issues, since the company is small and financing-dependent. - **Royalty revenue recognition** — Can create lumpy quarterly results - **Product sales recognition** — Affects quarter-to-quarter comparability - **Intangible assets** — Can affect asset values and expense recognition - **Going-concern and financing disclosures** — Important for assessing solvency and continuity - Royalty revenue is recognized when earned under license terms - Product sales are recognized at transfer of title - Intangible asset purchases can affect reported asset values - Debt and payables may require judgment on classification and measurement - Small-company financing can affect going-concern disclosures --- *Last updated: 2026-04-29T04:55:29.489431+00:00*